Target ACE2, Spike protein
(Die Seite wurde neu angelegt: „ACE2; any specific functions of spike protein; {{tp|p=32286790|t=ä. Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2 |pdf=|usr=}} {{tp|p=…“) |
|||
| Zeile 7: | Zeile 7: | ||
{{tp|p=32354636|t=ä. Blockade of SARS-CoV-2 infection by recombinant soluble ACE2 |pdf=|usr=}} | {{tp|p=32354636|t=ä. Blockade of SARS-CoV-2 infection by recombinant soluble ACE2 |pdf=|usr=}} | ||
{{tp|p=32332922|t=ä. SARS-CoV-2 infection of kidney organoids prevented with soluble human ACE2 |pdf=|usr=}} | {{tp|p=32332922|t=ä. SARS-CoV-2 infection of kidney organoids prevented with soluble human ACE2 |pdf=|usr=}} | ||
| + | {{tp|p=32294562|t=ä. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease |pdf=|usr=}} | ||
| + | {{tp|p=32359080|t=2020. Off-target ACE2 ligands: Possible therapeutic option for CoVid-19?|pdf=|usr=}} | ||
| + | {{tp|p=32167153|t=2020. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?|pdf=|usr=}} | ||
| + | {{tp|p=32373991|t=2020. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking |pdf=|usr=}} | ||
| + | |||
| + | {{tp|p=32362217|t=2020. In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria |pdf=|usr=}} | ||
| + | {{tp|p=32345124|t=2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets |pdf=|usr=}} | ||
Version vom 18. Juni 2020, 12:56 Uhr
ACE2; any specific functions of spike protein;
32286790 ä. Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2
32333836 ä. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
32125455 ä. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target
32231345 2020. Inhibition of SARS-CoV-2 (previously 2019-nCoV)infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
32354636 ä. Blockade of SARS-CoV-2 infection by recombinant soluble ACE2
32332922 ä. SARS-CoV-2 infection of kidney organoids prevented with soluble human ACE2
32294562 ä. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease
32359080 2020. Off-target ACE2 ligands: Possible therapeutic option for CoVid-19?
32167153 2020. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?
32373991 2020. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking
32362217 2020. In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria
32345124 2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets
